ALS blood test and new lung cancer combo + Neuroscience x Buddhism

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: Scientists reported a blood test that may spot ALS earlier; a new two-drug combo looked strong as the first treatment for lung cancer; engineered “good” bacteria fought tumors in animals; a key immune signal was shown to drive gut damage in celiac disease; and new nerve maps in diabetic neuropathy point to ways to calm inflammation.

Christin’s note: Continuing the thread on aspiration. Since I was a kid I’ve wanted to understand what really causes suffering and what actually leads to freedom, peace, and happiness. I went deep into neuroscience to study the “substrate” of mind, and I still love the scientific method. But when it came to relieving day-to-day unhappiness, Buddhist practice gave me the tools — a kind of gym workout for metacognition and self-awareness.

Pop in the Discord to chat and influence what Reframe Daily focuses on! →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: A blood test could spot ALS earlier and speed trial enrollment.

A plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosis

Market readiness: 🙂🙂 (human biomarker discovery with replication; needs prospective validation and regulatory clearance). 

Good news: A new drug combo showed strong first-line activity in advanced lung cancer.

First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial

Market readiness: 🙂🙂🙂 (phase 2 with promising efficacy; requires randomized phase 3 and FDA review). 

Good news: Programmable “good” bacteria attacked tumors in vivo, pointing to gentler cancer therapies.

Programmable immunoprobiotics orchestrate antitumor immune response with Pin1 inhibition

Market readiness: 🙂 (preclinical concept; years from clinical use). 

Good news: Pinpointing a key driver in celiac disease could lead to targeted treatments.

Interferon-γ is a direct driver of crypt hyperplasia in celiac disease

Market readiness: 🙂 (mechanism study identifying a druggable pathway; clinical trials still needed). 

Good news: New human nerve data in diabetic neuropathy map clear inflammatory targets.

Cell and molecular profiles in peripheral nerves shift toward inflammatory phenotypes in diabetic peripheral neuropathy

Market readiness: 🙂 (path-to-therapy insight; enables target selection but not yet a treatment).

Thank you for taking the time to take care of yourself and your loved ones.